Q2 EPS Estimate for Cogent Biosciences Raised by Analyst

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for Cogent Biosciences in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the technology company will post earnings of ($0.63) per share for the quarter, up from their previous forecast of ($0.64). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS and FY2027 earnings at $1.13 EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.04.

A number of other research firms have also weighed in on COGT. Scotiabank initiated coverage on Cogent Biosciences in a report on Friday, March 7th. They set a "sector outperform" rating and a $17.00 target price for the company. Robert W. Baird cut their price target on Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Wedbush reiterated a "neutral" rating and issued a $11.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, February 25th. HC Wainwright cut their price target on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, January 14th. Finally, Piper Sandler upgraded Cogent Biosciences to a "strong-buy" rating in a research note on Friday, March 7th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.29.

Cogent Biosciences Trading Down 2.2%

Shares of NASDAQ COGT traded down $0.11 during trading hours on Monday, reaching $4.88. The stock had a trading volume of 881,190 shares, compared to its average volume of 1,254,749. The firm has a market cap of $555.62 million, a price-to-earnings ratio of -1.97 and a beta of 1.91. The business's fifty day moving average price is $5.55 and its two-hundred day moving average price is $7.64. Cogent Biosciences has a 52-week low of $3.72 and a 52-week high of $12.61.

Institutional Investors Weigh In On Cogent Biosciences

Institutional investors have recently modified their holdings of the company. FMR LLC grew its stake in Cogent Biosciences by 99.2% during the 4th quarter. FMR LLC now owns 16,569,256 shares of the technology company's stock worth $129,240,000 after purchasing an additional 8,249,845 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cogent Biosciences by 7.3% in the 4th quarter. Vanguard Group Inc. now owns 6,133,380 shares of the technology company's stock valued at $47,840,000 after purchasing an additional 418,975 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its holdings in shares of Cogent Biosciences by 6.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,917,412 shares of the technology company's stock valued at $38,356,000 after purchasing an additional 307,650 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Cogent Biosciences by 5.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,300,000 shares of the technology company's stock valued at $33,540,000 after purchasing an additional 233,966 shares during the last quarter. Finally, Octagon Capital Advisors LP lifted its position in Cogent Biosciences by 111.7% during the 4th quarter. Octagon Capital Advisors LP now owns 2,763,000 shares of the technology company's stock worth $21,551,000 after acquiring an additional 1,458,000 shares during the period.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.